| STAT signaling in mammary gland differentiation, cell survival and tumorigenesis S Haricharan, Y Li Molecular and cellular endocrinology 382 (1), 560-569, 2014 | 143 | 2014 |
| Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data S Haricharan, MN Bainbridge, P Scheet, PH Brown Breast cancer research and treatment 146, 211-220, 2014 | 119 | 2014 |
| Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer JT Lei, J Shao, J Zhang, M Iglesia, DW Chan, J Cao, M Anurag, P Singh, ... Cell reports 24 (6), 1434-1444. e7, 2018 | 97 | 2018 |
| Endocrine therapy resistance: new insights JT Lei, M Anurag, S Haricharan, X Gou, MJ Ellis The Breast 48, S26-S30, 2019 | 93 | 2019 |
| TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth S Haricharan, P Brown Proceedings of the National Academy of Sciences 112 (25), E3216-E3225, 2015 | 85 | 2015 |
| Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers M Anurag, N Punturi, J Hoog, MN Bainbridge, MJ Ellis, S Haricharan Clinical Cancer Research 24 (19), 4887-4899, 2018 | 79 | 2018 |
| Loss of MutL disrupts CHK2-dependent cell-cycle control through CDK4/6 to promote intrinsic endocrine therapy resistance in primary breast cancer S Haricharan, N Punturi, P Singh, KR Holloway, M Anurag, J Schmelz, ... Cancer discovery 7 (10), 1168-1183, 2017 | 76 | 2017 |
| Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation JP Reddy, S Peddibhotla, W Bu, J Zhao, S Haricharan, YCN Du, ... Proceedings of the National Academy of Sciences 107 (8), 3728-3733, 2010 | 59 | 2010 |
| Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy S Haricharan, J Dong, S Hein, JP Reddy, Z Du, M Toneff, K Holloway, ... Elife 2, e00996, 2013 | 55 | 2013 |
| Segregating YKU80 and TLC1 alleles underlying natural variation in telomere properties in wild yeast G Liti, S Haricharan, FA Cubillos, AL Tierney, S Sharp, AA Bertuch, ... PLoS genetics 5 (9), e1000659, 2009 | 54 | 2009 |
| Ku must load directly onto the chromosome end in order to mediate its telomeric functions CR Lopez, A Ribes-Zamora, SM Indiviglio, CL Williams, S Haricharan, ... PLoS genetics 7 (8), e1002233, 2011 | 49 | 2011 |
| Luminal epithelial cells within the mammary gland can produce basal cells upon oncogenic stress SM Hein, S Haricharan, AN Johnston, MJ Toneff, JP Reddy, J Dong, W Bu, ... Oncogene 35 (11), 1461-1467, 2016 | 42 | 2016 |
| DNA damage repair defects as a new class of endocrine treatment resistance driver M Anurag, MJ Ellis, S Haricharan Oncotarget 9 (91), 36252, 2018 | 41 | 2018 |
| RETRACTED ARTICLE: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma A Garancher, H Suzuki, S Haricharan, LQ Chau, MB Masihi, JM Rusert, ... Nature neuroscience 23 (7), 842-853, 2020 | 37 | 2020 |
| Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization E Sajjadi, K Venetis, R Piciotti, M Invernizzi, E Guerini-Rocco, ... Cancer Cell International 21, 1-10, 2021 | 31 | 2021 |
| Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers K Venetis, E Sajjadi, S Haricharan, N Fusco Translational Cancer Research 9 (7), 4060, 2020 | 30 | 2020 |
| CDK4/6 inhibitor biomarker research: are we barking up the wrong tree? M Anurag, S Haricharan, MJ Ellis Clinical Cancer Research 26 (1), 3-5, 2020 | 23 | 2020 |
| Contribution of an alveolar cell of origin to the high-grade malignant phenotype of pregnancy-associated breast cancer S Haricharan, SM Hein, J Dong, MJ Toneff, OH Aina, PH Rao, RD Cardiff, ... Oncogene 33 (50), 5729-5739, 2014 | 19 | 2014 |
| Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer NB Punturi, S Seker, V Devarakonda, A Mazumder, R Kalra, CH Chen, ... Nature communications 12 (1), 2940, 2021 | 17 | 2021 |
| HER2 activation and endocrine treatment resistance in HER2-negative breast cancer A Mazumder, S Shiao, S Haricharan Endocrinology 162 (10), bqab153, 2021 | 15 | 2021 |
Paul ScheetUniversity of Texas MD Anderson Cancer CenterAdresse e-mail validée de mdanderson.org
